| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.008 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.0078 | 0.9 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | 0.009 | 0.9 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |